You are here: Industry Insights > ARB

News List

Hypertension: study suggests ARBs should be used before ACE inhibitors pharmaceutical-technology
July 29, 2021
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are both recommended, first-line treatments for hypertension, or high blood pressure.
FDA announces expansion of generic impurity investigation europeanpharmaceuticalreview
September 02, 2019
The examination of ARB drugs by the FDA will be extended to include other generics with similar manufacturing processes to identify impurities.
FDA: Statement on the Agency’s Ongoing Efforts to Resolve Safety Issue with ARB Medications drugs
August 29, 2019
Protecting patients is the FDA’s highest priority, and Americans can be confident in the quality of the products the agency approves.
New generic valsartan approved to address shortages europeanpharmaceuticalreview
April 12, 2019
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers…
NEWS FDA finds another carcinogenic impurity in ARB blood pressure drug europeanpharmaceuticalreview
April 10, 2019
FDA is ‘deeply concerned’ about a third type of nitrosamine impurity detected in angiotensin II receptor blocker (ARB) medicines…
FDA Approves New Generic Valsartan to Ease Shortage drugs
March 14, 2019
The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage.
FDA provides Update on ARB Drug Product Investigation americanpharmaceuticalreview
March 06, 2019
The U.S. Food and Drug Administration (FDA) is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and
FDA announces another carcinogenic impurity in ARB blood pressure drugs pharmaceutical-technology
March 05, 2019
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for high blood pressure and heart failure.
FDA updates on angiotensin II receptor blocker (ARB) recalls fda
November 15, 2018
FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot – JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg tablets, that contain losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothi